The evolution from slow freezing to vitrification has transformed oocyte cryopreservation into a reliable, evidence-based option for fertility preservation, shifting the balance of clinical decision-making from technical limitations towards reproductive autonomy. While embryo cryopreservation historically offered higher success rates, contemporary vitrification enables comparable outcomes, allowing patients to retain greater control over their reproductive future without premature commitment to a partner or donor sperm.

This narrative review critically explores the ethical, clinical, and psychosocial dimensions of prioritising oocyte autonomy in fertility preservation, with particular attention to age-stratified outcomes, return-to-use rates, and diverse patient groups including cancer patients, those undertaking elective (social) egg freezing, and transgender individuals. We argue that the marginal efficacy advantage of embryos does not outweigh the importance of autonomy, provided counselling remains transparent, evidence-driven, and sensitive to individual circumstances.

Evidence was identified through targeted review of peer-reviewed publications, professional society guidelines (ESHRE, ASRM), and national and international registry reports relevant to oocyte and embryo cryopreservation. Particular emphasis was placed on prospective studies, sibling-oocyte and donor-oocyte comparisons, large observational cohorts, and long-term follow-up studies. A formal systematic review or meta-analysis was not undertaken due to substantial heterogeneity in study design, populations, outcome definitions, and denominators.

Contemporary evidence from donor programmes and sibling-oocyte designs demonstrates post-warming survival commonly exceeding 85–90%, with fertilisation, embryo development, implantation, and ongoing pregnancy rates comparable between vitrified-warmed and fresh oocytes in younger, good-prognosis patients. However, the strongest data derive from donor settings; evidence in older autologous populations is limited. Embryo cryopreservation retains advantages in specific clinical scenarios, including older patients with limited oocyte yield. Autonomy is further constrained by uneven access, funding disparities, and variable policy frameworks worldwide. Return-to-use rates remain low (typically <16%), and long-term outcome data from elective oocyte cryopreservation are still sparse. Counselling quality, evidence-based age-stratified information, and attention to psychosocial needs emerge as central determinants of genuine patient empowerment.

True empowerment in fertility preservation depends not only on scientific progress but also on equitable access, consistent evidence-based counselling, and embedding psychological and identity-sensitive support into clinical practice. The emerging importance of long-term cryostorage stewardship, dynamic consent, and environmental sustainability should be integrated as components of ethical, patient-centred fertility preservation services.